L

ast April, the Food and Drug Administration alerted an untold number of drug makers that marketing applications containing clinical trial data prepared by Semler Research Center, an Indian contract research organization, would not be accepted due to concerns about the integrity of the data.

Now, the company has filed a lawsuit seeking $50 million in damages and accusing the agency of a lack of due process, exposure to claims from customers totaling about $20 million, and the loss of a potential sale that could have yielded $30 million. In short, Stemler alleges the FDA caused a “stigma (that) led to the complete annihilation” of its business.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.